{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:48:32Z","timestamp":1792147712074,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.aprim.2026.103610","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:53:30Z","timestamp":1789502010000},"page":"103610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinantes del riesgo hemorr\u00e1gico en pacientes anticoagulados en atenci\u00f3n primaria: estudio observacional retrospectivo"],"prefix":"10.1016","volume":"58","author":[{"given":"Florin Radu","family":"Ciorba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis El\u00edas","family":"Mart\u00ednez-Tittonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bayona-Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2026.103610_bib0110","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J."},{"key":"10.1016\/j.aprim.2026.103610_bib0115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.aprim.2026.103610_bib0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.aprim.2026.103610_bib0125","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace."},{"key":"10.1016\/j.aprim.2026.103610_bib0130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2026.103610_bib0135","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2026.103610_bib0140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2026.103610_bib0145","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2026.103610_bib0150","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2026.103610_bib0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.aprim.2026.103610_bib0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","author":"Lip","year":"2016","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.aprim.2026.103610_bib0165","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/ijcp.12863","article-title":"Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: A \u201creal-world\u201d observational study in the United States","volume":"70","author":"Lip","year":"2016","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.aprim.2026.103610_bib0170","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.aprim.2026.103610_bib0175","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001257","article-title":"Polypharmacy and health outcomes in atrial fibrillation: A systematic review and meta-analysis","volume":"7","author":"Gallagher","year":"2020","journal-title":"Open Heart."},{"key":"10.1016\/j.aprim.2026.103610_bib0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0043-1769735","article-title":"The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"124","author":"Grymonprez","year":"2024","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.aprim.2026.103610_bib0185","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s11845-019-02150-0","article-title":"Monitoring of atrial fibrillation in primary care patients prescribed direct oral anticoagulants for stroke prevention","volume":"189","author":"Murphy","year":"2020","journal-title":"Ir J Med Sci."},{"key":"10.1016\/j.aprim.2026.103610_bib0190","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.aprim.2026.103610_bib0195","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost."},{"issue":"4 Suppl","key":"10.1016\/j.aprim.2026.103610_bib0200","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.aprim.2026.103610_bib0205","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.aprim.2026.103610_bib0210","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","article-title":"Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study","volume":"54","author":"Fang","year":"2006","journal-title":"J Am Geriatr Soc."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021265672600168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021265672600168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:14:30Z","timestamp":1792145670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021265672600168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S021265672600168X"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2026.103610","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinantes del riesgo hemorr\u00e1gico en pacientes anticoagulados en atenci\u00f3n primaria: estudio observacional retrospectivo","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2026.103610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103610"}}